相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis
Li Jia et al.
CANCER LETTERS (2013)
Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis
Srdan Verstovsek
POSTGRADUATE MEDICINE (2013)
A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy
Rebekka Kubisch et al.
TRANSLATIONAL ONCOLOGY (2013)
Low-Dose Docetaxel Combined with (-)-Epigallocatechin-3-Gallate Inhibits Angiogenesis and Tumor Growth in Nude Mice with Gastric Cancer Xenografts
Hongju Wu et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2012)
Phase II trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer
S. D. Young et al.
CURRENT ONCOLOGY (2012)
FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer
Paula Paulo et al.
GENES CHROMOSOMES & CANCER (2012)
Strategies for Improving the Clinical Benefit of Antiangiogenic Drug Based Therapies for Breast Cancer
Robert S. Kerbel
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2012)
Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts
Ines Martin-Padura et al.
LABORATORY INVESTIGATION (2012)
Managing drug resistance in cancer: lessons from HIV therapy
Christoph Bock et al.
NATURE REVIEWS CANCER (2012)
Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer
Ibrahim A. Aljuffali et al.
CANCER BIOLOGY & THERAPY (2011)
Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model
Hongju Wu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer - Review of the literature
T. Nelius et al.
CANCER TREATMENT REVIEWS (2011)
Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor
Sushil Kumar et al.
CLINICAL CANCER RESEARCH (2011)
Cancer Predisposing Mutations in BRCT Domains
Alessandra di Masi et al.
IUBMB LIFE (2011)
Treatment-Related Mortality With Bevacizumab in Cancer Patients A Meta-analysis
Vishal Ranpura et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer
Raquel De Souza et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide
Urban Emmenegger et al.
NEOPLASIA (2011)
Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients Phase I ZANTE trial
Gaetano Facchini et al.
CANCER BIOLOGY & THERAPY (2010)
Oncogenic Partnerships: EWS-FLI1 Protein Interactions Initiate Key Pathways of Ewing's Sarcoma
Hayriye V. Erkizan et al.
CLINICAL CANCER RESEARCH (2010)
Metronomic Chemotherapy for Metastatic Prostate Cancer A 'Young' Concept for Old Patients?
Andrea Fontana et al.
DRUGS & AGING (2010)
In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy
Lilja Thoenes et al.
JOURNAL OF PROTEOMICS (2010)
METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION-RESISTANT PROSTATE CANCER
Andrea Fontana et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2010)
Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer
Raquel De Souza et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer
Kae Hashimoto et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Metronomic chemotherapy: new rationale for new directions
Eddy Pasquier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma
William M. Merritt et al.
CANCER BIOLOGY & THERAPY (2009)
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy
John M. L. Ebos et al.
CLINICAL CANCER RESEARCH (2009)
Oral Uracil and Tegafur Compared With Classic Cyclophosphamide, Methotrexate, Fluorouracil As Postoperative Chemotherapy in Patients With Node-Negative, High-Risk Breast Cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial
Toru Watanabe et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Da Wei Huang et al.
NATURE PROTOCOLS (2009)
Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists
Da Wei Huang et al.
NUCLEIC ACIDS RESEARCH (2009)
Resistance to chemotherapy:: new treatments and novel insights into an old problem
S. Raguz et al.
BRITISH JOURNAL OF CANCER (2008)
Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles
Sharon L. Sanborn et al.
INVESTIGATIONAL NEW DRUGS (2008)
A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC)
Michael Goern et al.
ONKOLOGIE (2008)
The therapeutic potential of a series of orally bioavailable antiangiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers
S. P. Newman et al.
BRITISH JOURNAL OF CANCER (2007)
Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer
L. Tam et al.
BRITISH JOURNAL OF CANCER (2007)
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors
Chris Folkins et al.
CANCER RESEARCH (2007)
Nonreceptor tyrosine kinases in prostate cancer
Yu-Ming Chang et al.
NEOPLASIA (2007)
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer
Aparna A. Kamat et al.
CANCER RESEARCH (2007)
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients
Alberto Bottini et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: A well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia
U Emmenegger et al.
CANCER RESEARCH (2006)
Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts
JM du Manoir et al.
CLINICAL CANCER RESEARCH (2006)
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
Y Shaked et al.
BLOOD (2005)
Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy
Y Shaked et al.
CANCER RESEARCH (2005)
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations:: Modulation by lower-dose chemotherapy
L Ma et al.
CANCER RESEARCH (2005)
Timeline - Chemotherapy and the war on cancer
BA Chabner et al.
NATURE REVIEWS CANCER (2005)
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
H Kato et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The anti-angiogenic basis of metronomic chemotherapy
RS Kerbel et al.
NATURE REVIEWS CANCER (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
G Bocci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Significance analysis of microarrays applied to the ionizing radiation response
VG Tusher et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
G Klement et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
